Raf kinase inhibitor protein (RKIP) may be a suppressor of metastasis: RKIP levels are high in normal tissues, low in primary cancers and lowest or absent in metastatic cancers. This immunohisto chemistry study investigated RKIP protein levels in 250 clinical specimens of human cervical tissue and lymph node metastases (LNM) from 210 patients with normal cervical tissue, cervical intra-epithelial neoplasia (CIN), or cervical cancer with/without LNM. Thirtynine (86.7%) of the 45 normal-tissue samples were RKIP-positive, six (13.3%) were RKIP-negative; 48/60 (80.0%) CIN samples were positive, 12 (20.0%) were negative; 47/105 (44.8%) cervical cancer tissue samples were positive, 58 (55.2%) were negative; only 7/40 (17.5%) LNM tissue samples were positive, 33 (82.5%) were negative. There was no significant correlation between RKIP positivity and clinical stage, microscopic subtype or pathological differentiation grade. RKIP positivity correlated inversely with LNM. RKIP may play a role in cervical-cancer genesis and metastasis; RKIP downregulation was associated with metastatic disease in human cervical cancer.
Introduction
Cervical cancer is the second most common cancer among women worldwide, both in terms of incidence and related mortality rates. 1 The main causes of cervical cancerrelated death are recurrence of the cancer and/or metastasis. Metastasis remains one of the most important but least understood aspects of cancer, and increasing knowledge of the mechanisms by which metastasis occurs may help to identify therapeutic targets. 2 Raf kinase inhibitor protein (RKIP) is a member of an evolutionarily conserved group of proteins, the phosphatidylethanolamine-binding proteins, which have a CJ Hu and L Zhou contributed equally to this article. b CJ Hu is now at Department of Obstetrics and Gynaecology, The Fourth Affiliated Hospital, Harbin Medical University, Harbin City, China. Raf kinase inhibitor protein in cervical cancer tissue been identified as suppressors of metastasis. 3 At the molecular level, RKIP functions by inhibiting the proliferative and survival signalling pathways of Raf-mitogenactivated protein kinase-extracellularsignal-regulated kinase, and nuclear factor κ-light chain enhancer of activated B cells (NF-κB). 4, 5 The NF-κB pathway is often hyperactivated in cervical cancers. 6 RKIP is down-regulated in a number of tumours, including highly metastatic prostate, 2,4 breast 4,7 and colon cancer, 8 hepatocellular carcinoma, 9 melanomas, 10 gastric cancer, 11 ovarian cancer 12 and insulinoma. 13 The function of RKIP in cervical cancer has not, however, been reported. The aims of the present study were to conduct a detailed immunohistochemical analysis of RKIP protein in non-neoplastic cervical tissue and cervical cancer tissue, and to evaluate the role of RKIP in the genesis and metastasis of cervical cancer.
Patients and methods

PATIENTS AND INCLUSION CRITERIA
Archived formalin-fixed paraffin-embedded tissue samples from patients with normal cervical tissues, cervical intraepithelial neoplasia (CIN) or cervical cancers, obtained between 2002 and 2009, were retrieved from the Surgical Pathology Department of The Fourth Affiliated Hospital of Harbin Medical University, Harbin City, China. In addition, samples of lymph node metastatic tissue (from patients with cervical cancer and positive lymph-node involvement) were retrieved.
Samples were preserved sequentially from each patient undergoing surgery. No specific inclusion or exclusion criteria were used, other than that cervical cancer patients had not received chemotherapy or radiotherapy before surgery.
Ethical approval for the study was provided by the Ethics Committee of the Fourth Affiliated Hospital of Harbin Medical University. The patients participating in the study provided verbal informed consent.
IMMUNOHISTOCHEMISTRY
All the specimens were deparaffinized, rehydrated in graded alcohols and subjected to heat-induced epitope retrieval in 0.1 M citrate buffer solution, pH 6.0, in a microwave oven for 20 min. The slides were then incubated with a polyclonal rabbit antibody raised against amino acids 1 -187, which represents full-length RKIP of human origin (1:100 dilution; Santa Cruz Biotechnology, Santa Cruz, CA, USA), for 1 h at room temperature, according to the manufacturer's instructions. The sections were washed three times in 0.01 M phosphate-buffered saline (PBS), pH 7.4, to remove the primary antibody. Next, the slides were incubated with goat antirabbit secondary antibody (1:50 dilution) for 30 min at 37°C, then with 50 µl biotin-free horseradish peroxidase enzyme-labelled polymer for 10 min at 37°C (both from an Elivision Plus detection kit; Maixin-Bio, Fuzhou, China), and washed a final three times in 0.01 M PBS. Finally, 50 µl 3,30diaminobenzidine was added to the slides as the chromogen (Maixin-Bio) and the sections were counterstained with haematoxylin. Normal cervical tissues were used as positive controls, and omission of the primary antibody served as the negative control. All slides were examined and scored by two independent pathologists who were unaware of both clinical and pathological data. Scoring was carried out for both the percentage of positive cells and the intensity of staining. Briefly, the score was the sum of the percentage of positive cells (1, < 25% positive cells; 2, 26% -50% positive cells; and 3, > 50% positive cells) and the staining intensity (0, Raf kinase inhibitor protein in cervical cancer tissue negative; 1, weak; 2, moderate; 3, strong). Total scores between 1 and 2 were graded as negative, scores of 3 and 4 were graded as weakly positive, and scores of 5 and 6 were graded as positive, as reported previously. 8
STATISTICAL ANALYSES
The strength of agreement between the two independent pathologists' results was calculated by using a linear weighted κfactor and they were found to correlate well (κ = 0.81). Statistical analyses were carried out using the SPSS ® statistical package, version 13.0 (SPSS Inc., Chicago, IL, USA) for Windows ® . Data were analysed using the χ 2test. All statistical tests were two sided and a P-value < 0.05 was considered to be statistically significant.
Results
PATIENTS AND SAMPLES
In total, 250 samples were used in the study. These comprised cervical tissue samples from 210 patients: 105 patients with cervical cancer; 45 patients with normal cervical tissue resected because of uterine myoma and other diseases; and 60 patients with CIN (including CIN I, CIN II and CIN III). Samples of 40 affected lymph node tissues from patients with cervical cancer metastases were also used. Of the 105 patients with cervical cancer, with respect to pathological type, 65 patients did not have metastases and 40 patients had lymph node metastases; 32 had cervical squamous cell carcinoma, 40 had cervical adenocarcinoma and 33 had cervical adenosquamous carcinoma; 35 had welldifferentiated cervical cancer, 40 cancers were moderately differentiated, and 30 were poorly differentiated. In terms of clinical stage, 20 had cervical cancer in situ (clinically equivalent to stage 0), 41 cancers were classified as being stage Ia, 21 were Ib, and 23 were stage IIa according to the standards of the International Federation of Obstetrics and Gynecology. 14
RKIP PROTEIN DETECTION
Using immunohistochemistry, RKIP protein was localized predominantly in the cytoplasm of the tumour tissue and the surrounding connective tissue, although some nuclear staining in the tumour itself was also noted. The majority of normal cervical tissue samples analysed in this study (86.7%, 39/45) showed positive immunostaining for RKIP ( Fig. 1, Table 1 ). Data presented as n (%) of patients. a Normal cervical tissue versus: CIN χ 2 = 0.805, P > 0.05 (not statistically significant); cervical cancer χ 2 = 22.61, P < 0.001; and lymph node metastasis χ 2 = 40.80, P < 0.001. b CIN versus: cervical cancer χ 2 = 19.41, P < 0.001; and lymph node metastasis χ 2 = 37.88, P < 0.001. c Cervical cancer versus lymph node metastasis χ 2 = 9.21, P = 0.002.
TABLE 1:
The proportion of cervical cancer tissue samples (with or without lymph node metastasis) that were negative, weakly positive or positive for Raf kinase inhibitor protein, as detected by immunohistochemical staining, compared with normal cervical tissue and cervical intraepithelial neoplasia (CIN) tissue samples Raf kinase inhibitor protein in cervical cancer tissue significantly higher among normal cervical tissue samples than in those from patients with cervical cancer (χ 2 = 22.61, P < 0.001; Table 1 ). The percentage of patients positive for RKIP protein was also significantly higher among all patients with cervical cancer (Fig.  2 ) than among those with lymph node metastases (χ 2 = 9.21, P = 0.002; Table 1 ). No correlation was found between RKIP positivity and established clinical features including microscopic subtype, pathology, differentiation grade or clinical stage.
RKIP IN METASTATIC CERVICAL CANCER
Compared with lymph node-negative cervical cancers, there was a decrease in the frequency of RKIP-positive samples among lymph node-positive cervical cancers ( Fig. 3) , which was highly consistent and statistically significant (χ 2 = 10.341, P = 0.001; Table 2 ). RKIP positivity was lowest among patients with lymph node metastasis, suggesting that down-regulation of RKIP is a hallmark of metastatic disease in human cervical cancer. proximal kidney tubule epithelium, enterocytes, goblet cells and plasma cells of the small intestine, plasma cells of the lymph node, plasma cells and megakaryocytes of the spleen, heart, liver, epididymis, lung bronchioles, mesenteric lymph node, oviduct, ovary, lactating mammary glands, uterus, prostate epithelium and thyroid. 2, 15 The wide distribution of RKIP in many different tissue types suggests that it plays a role in a multitude of different physiological processes. 16 RKIP has been shown to be present at low levels (or completely absent) in many cancers including prostate cancer, 2,17 breast cancer, 4,7 melanoma 5,10 and insulinoma. 13 The frequency of tissue samples that were positive for RKIP protein in the present study was significantly reduced in patients with cervical cancer with lymph node metastases versus those without metastases. Previous studies with cultured tumour cells derived from melanoma, prostate, ovary and breast cancers have indicated that RKIP is a strong candidate for being a suppressor of metastasis. 2, 4, 8, 10 The present study is the first large scale study to be reported, using clinical material from 210 patients. The results fully support the conclusion that, in cervical cancers, RKIP is a suppressor of metastasisthat is, defined as suppressing metastasis without affecting tumorigenicity 18 -as the protein was consistently down-regulated in tissue samples from cervical cancer patients with lymph node metastases, but not in those without lymph node metastases. RKIP has been reported to be down-regulated or undetectable in colorectal cancer metastases and breast cancer metastases. 19, 20 Similarly, in the present study, the percentage of metastatic lymph node tissues that were positive for RKIP protein was only 5.0%: far lower than that observed in samples of cervical cancer tissue without metastases (15.2%). Thus, the present study suggested that RKIP may play a role in the metastasis of cervical cancer.
In breast cancer, no significant correlation has been observed between RKIP and 20 Similarly, in the present study there was no correlation between positive immunostaining for RKIP and cancer pathology subtype, differentiation grade or clinical stage. Results from studies on prostate cancers and colon cancers have shown that RKIP protein levels were lower in tissue samples from patients with metastasis, compared with those who did not have metastasis. 2, 19 Thus, we suggest that RKIP is a suppressor of metastasis in cervical cancer. Additionally, as the proportion of cervical cancer patients who were positive for RKIP protein was significantly lower than the proportion of patients with CIN or normal cervical tissues who were positive for RKIP, it could be suggested that RKIP plays an important role in the genesis of cervical cancer and in the progression of CIN to cervical cancer.
Regardless of the exact mechanism of RKIP function, the significant downregulation of RKIP in metastatic tissue could provide a new therapeutic target for the treatment of metastatic cervical cancer. Preliminary observations show that RKIP protein can be induced by ionizing radiation 21 or by chemotherapy drugs. 4 As both regimens are part of the current clinical armoury, it will be worth investigating further whether regulating RKIP contributes to their therapeutic efficacy, thereby providing a potentially valuable treatment strategy for cervical cancer.
